Bisphosphonate-Associated Osteonecrosis of The Jaw : Reports of bisphosphonate-associated osteonecrosis of the jaw (BON) associated with the use of Zometa (zolendronic acid) and Aredia (pamidronate) began to surface in 2003. The majority of reported cases have been associated with dental procedures such as tooth extraction; however, less commonly BON appears to occur spontaneously in patients taking
The zebra stripe sign occurs where children with osteogenesis imperfecta have been treated with cyclical bisphosphonate therapy, e.g. pamidronate. When the drug is delivered in cycles, dense bone is formed while treatment is being given. This results in dense stripes across the metaphyses of bones which can be visualized radiographically.
STUDY: Bisphosphonate use INCREASES Fracture Risk 100x Study shows #atypical fracture risk is 100x higher with #bisphosphonate use. The longer the bisphosphonate use, the greater your risk of #fracture.
A routine treatment of Zometa for Zurk at Parkway Cancer Centre in Singapore. Zoledronic acid (INN) or zoledronate (marketed by Novartis under the trade names Zometa, Zomera, Aclasta and Reclast) is a bisphosphonate. Bisphosphonates are a class of drugs that prevent the loss of bone mass.
Fractures are increased and Bisphosphonate use decreased in individuals with insulin-dependent diabetes: a 10 year cohort study. READ MORE: https://www.worldnewsmd.com/Article/Orthopedics/Fractures-Are-Increased-In-Individuals-With-Insulin-Dependent-Diabetes #Diabetes #InsulinFractures #ClinicalTrials
Fosamax a bad drug in litigation 3/26/15 Physicans are seeing and reporting more cases of atypical femur fractures on Fosamax. These are spontaneous fractures with no trauma indicating underlying pathologic bone formation. We never saw these before the fosamax era. Dentists report(s) of a link with Osteonecrosis of the Jaw, another example of fosamax disturbing bone physiology, making the bones weaker, not stronger. In spite of Dr Black’s reassuring report, Dr Elizabeth Shane still…
Canadense cria creme capaz de remover tatuagem sem dor
Alec Falkenham estuda Patologia na Universidade de Dalhousie e diz ter resolvido investir na criação do Bisphosphonate Liposomal Tattoo (BLTR), nome de batismo do creme, depois de fazer sua primeira tatuagem e o medo de se arrepender no futuro.